GlaxoSmithKline Signs Contract for its Pandemic Flu Vaccine with UK Government

GlaxoSmithKlineGlaxoSmithKline (GSK) today announced that it has entered into an agreement with the UK Government to provide its pandemic influenza vaccine in the event of a flu pandemic. It is one of the largest contracts signed by GSK to date for its proprietary adjuvanted pandemic flu vaccine.

As part of an Advance Supply Agreement, GSK has committed to make the necessary preparations to supply its pandemic influenza vaccine as soon as possible after a pandemic outbreak has been declared.ntracts signed by GSK to date for its proprietary adjuvanted pandemic flu vaccine. GSK plans to supply a 'tailored' pandemic vaccine as and when the pandemic strain is identified and made available by the World Health Organisation (WHO).

Andrew Witty, President GSK Pharmaceuticals Europe, said: "This agreement underlines GSK's commitment to supporting the UK Government in its plans against a possible influenza pandemic. Vaccines are considered to be the single most important intervention for preventing influenza infection and reducing spread of the disease. They are a critical component of any response plan aimed at reducing the potentially devastating effects of an influenza pandemic. GSK believes that securing a pandemic vaccine supply is an important step towards full pandemic preparedness and ultimately the protection of the British public."

The WHO has stated that an influenza pandemic poses a serious global public health threat with substantial estimated morbidity and mortality. GSK is committed to supporting governments and health authorities around the world in planning to respond to a global influenza pandemic, both prior to an outbreak and in the event one is officially declared. This latest agreement with the UK Government follows recent supply agreements signed with the Swiss, Danish and Icelandic governments. GSK has applied for registration of its pandemic vaccine in January, 2007 to the EMEA.

Professor John Oxford, Professor of Virology, Queen Mary's School of Medicine, St Bartholomew#s and the Royal London Hospitals, and Scientific Director of Retroscreen Virology Ltd said: "This announcement by the UK Government is very good news. The World Health Organisation and experts across the globe agree that an influenza pandemic is likely to occur, but cannot predict when. Despite this uncertainty, there is still the opportunity to be thoroughly prepared. This agreement is part of the preparation needed to protect the UKpopulation when an influenza pandemic eventually strikes."

The pandemic vaccine utilises GSK's proprietary adjuvant system technology which has been shown to reduce the amount of antigen required to elicit a seroprotective response – the so-called 'antigen-sparing' effect. This allows a greater number of vaccine doses to be produced when antigen availability is likely to be limited, thereby offering the potential for vaccination to more people in the event of a flu pandemic. In recent pre-clinical trials the adjuvanted vaccine has shown the potential to recognize different H5N1 viruses and to induce cross-protection.

Since 2000, GSK has made substantial progress in its pandemic influenza vaccine development programme and continues to investigate ways to further improve vaccination strategies to respond to a pandemic. To this end, more than $2 billion has already been invested by GSK in combating avian flu; increasing GSK's production capacity for influenza vaccines and GSK's anti-viral flu treatment Relenza® (zanamivir), and in ensuring the continuity of critical business operations and processes, to safeguard the continued supply of critical medicines.

About GlaxoSmithKline
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at www.gsk.com

Most Popular Now

Novartis research shows technology talent increasi…

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing res...

GSK COVID-19 vaccine development collaboration wit…

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiati...

Lilly begins world's first study of a potential CO…

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This inve...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

Sanofi and Translate Bio expand collaboration to d…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to ...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Bayer supports "The Challenge Initiative…

Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...